Healius Ltd (ASX: HLS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Healius Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $929.41 million
P/E Ratio 55.56
Dividend Yield 0.00%
Shares Outstanding 726.10 million
Earnings per share -1.646
Dividend per share 0.12
Year To Date Return -22.02%
Earnings Yield 1.80%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Healius Ltd (ASX: HLS)
    Latest News

    An executive stands looking out a glass window over the city.
    Share Market News

    6 ASX 200 directors buying up their companies' shares this week

    Insider buying is generally thought to be a sign those in the know expect big things of a stock.

    Read more »

    A man sitting at his dining table looks at his laptop and ponders the CSL balance sheet and the value of CSL shares today
    Share Market News

    5 things to watch on the ASX 200 on Monday

    The ASX 200 is expected to start the week deep in the red...

    Read more »

    A man leans back with his hands behind his head and feet on his desk with a big smile on his face at his success.
    Dividend Investing

    3 ASX shares I'd buy for passive income instead of BHP's declining dividend

    Worried about further weakness in BHP's dividend? Here are a few options I'd look at to fortify the money printer.

    Read more »

    Group of people cheer around tablets in office
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Which ASX 200 share gained the most on the back of earnings today?

    Read more »

    Top ten gold trophy.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Guess which embattled ASX 200 stock just posted today's biggest gain.

    Read more »

    A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
    Healthcare Shares

    Why did ASX 300 healthcare stock Polynovo tumble 12% today?

    Polynovo had a shocker on Wednesday. Let's look at why...

    Read more »

    A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
    Share Fallers

    Why Amcor, Dicker Data, Elders, and Healius shares are dropping today

    These ASX shares are having a difficult time on Wednesday afternoon...

    Read more »

    Worried ASX share investor looking at laptop screen
    Share Fallers

    Why Appen, Gold Road, Healius, and Pinnacle shares are dropping today

    These ASX shares are having a tough time on Wednesday...

    Read more »

    A group of businesspeople clapping.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    Gold shares reined supreme on Friday.

    Read more »

    dissapointed man at falling share price
    Share Fallers

    These were the worst performing ASX 200 shares in November

    These ASX 200 shares missed out on the good times in November...

    Read more »

    Two mature women learn karate for self defence.
    Healthcare Shares

    3 ASX shares to combat the next market dip: experts

    Defence and offence at the same time: this trio of stocks also has excellent growth potential.

    Read more »

    A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
    Share Fallers

    Why Fortescue, Healius, Nanosonics, and PEXA shares are dropping

    These ASX shares are starting the week in the red...

    Read more »

    Frequently Asked Questions

    Yes, Healius has historically paid two fully franked shareholder dividends a year.

    Healius has generally paid its shareholder dividends in March/April and September/October.

    Healius Ltd listed on the ASX on 3 July 1998.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    07 Sep 2022 $0.0600 100.00% Final 21 Sep 2022
    24 Mar 2022 $0.1000 100.00% Interim 05 Apr 2022
    13 Sep 2021 $0.0675 100.00% Final 08 Oct 2021
    25 Mar 2021 $0.0650 100.00% Interim 15 Apr 2021
    26 Mar 2020 $0.0260 100.00% Interim 15 Oct 2020
    29 Aug 2019 $0.0340 100.00% Final 27 Sep 2019
    15 Mar 2019 $0.0380 100.00% Interim 26 Mar 2019
    27 Aug 2018 $0.0550 100.00% Final 17 Sep 2018
    16 Mar 2018 $0.0510 100.00% Interim 27 Mar 2018
    31 Aug 2017 $0.0000 100.00% Final 18 Sep 2017
    17 Mar 2017 $0.0480 100.00% Interim 28 Mar 2017
    01 Sep 2016 $0.0640 100.00% Final 19 Sep 2016
    18 Mar 2016 $0.0560 50.00% Interim 29 Mar 2016
    26 Aug 2015 $0.1100 50.00% Final 14 Sep 2015
    18 Mar 2015 $0.0900 100.00% Interim 07 Apr 2015
    27 Aug 2014 $0.1100 100.00% Final 15 Sep 2014
    17 Mar 2014 $0.0900 100.00% Interim 07 Apr 2014
    16 Sep 2013 $0.1100 100.00% Final 08 Oct 2013
    18 Mar 2013 $0.0650 100.00% Interim 08 Apr 2013
    17 Sep 2012 $0.0600 100.00% Final 08 Oct 2012
    26 Mar 2012 $0.0500 100.00% Interim 16 Apr 2012
    19 Sep 2011 $0.0500 100.00% Final 10 Oct 2011
    21 Mar 2011 $0.0300 100.00% Interim 11 Apr 2011
    20 Sep 2010 $0.1000 100.00% Final 11 Oct 2010
    05 Mar 2010 $0.1500 100.00% Interim 29 Mar 2010
    07 Sep 2009 $0.0700 100.00% Final 28 Sep 2009
    16 Feb 2009 $0.0700 100.00% Interim 09 Mar 2009
    08 Sep 2008 $0.0500 100.00% Final 09 Oct 2008
    22 Feb 2008 $0.2200 100.00% Interim 17 Mar 2008
    31 Aug 2007 $0.2400 100.00% Final 24 Sep 2007
    09 Mar 2007 $0.2100 100.00% Interim 02 Apr 2007
    09 Oct 2006 $0.0800 100.00% Special Cash 30 Oct 2006
    04 Sep 2006 $0.2200 100.00% Final 25 Sep 2006
    20 Feb 2006 $0.2000 100.00% Interim 13 Mar 2006
    22 Aug 2005 $0.1300 100.00% Final 12 Sep 2005
    08 Apr 2004 $0.0750 100.00% Interim 03 May 2004

    HLS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Healius Ltd

    Healius Ltd (ASX: HLS) operates a network of pathology laboratories, diagnostic imaging centres, and day hospitals across Australia.

    The company is Australia's second-largest pathology provider with around 2,000 collection sites and almost 100 pathology laboratories operating under a portfolio of brand names. The company says one in three pathology samples taken in Australia is tested in a Healius laboratory. It also operates around 150 imaging centres in public and private hospitals, medical centres, and community centres. 

    The company has identified its short-stay and day hospitals as a growth segment. It currently operates 15 day hospitals as well as four major IVF clinics. 

    HLS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Mar 2024 $1.28 $0.01 0.78% 1,519,810 $1.29 $1.29 $1.26
    26 Mar 2024 $1.28 $-0.02 -1.55% 1,409,410 $1.30 $1.31 $1.26
    25 Mar 2024 $1.29 $0.03 2.38% 2,766,531 $1.26 $1.32 $1.26
    22 Mar 2024 $1.26 $0.01 0.80% 3,192,190 $1.23 $1.28 $1.21
    21 Mar 2024 $1.25 $0.04 3.32% 5,136,980 $1.21 $1.25 $1.21
    20 Mar 2024 $1.21 $0.01 0.84% 3,110,887 $1.20 $1.22 $1.19
    19 Mar 2024 $1.20 $0.00 0.00% 2,577,019 $1.20 $1.22 $1.17
    18 Mar 2024 $1.20 $-0.06 -4.76% 4,995,215 $1.25 $1.26 $1.20
    15 Mar 2024 $1.26 $-0.01 -0.79% 4,867,147 $1.25 $1.29 $1.25
    14 Mar 2024 $1.27 $-0.02 -1.54% 3,579,164 $1.28 $1.30 $1.26
    13 Mar 2024 $1.30 $-0.06 -4.43% 1,782,787 $1.34 $1.37 $1.30
    12 Mar 2024 $1.36 $0.04 3.05% 3,255,525 $1.31 $1.38 $1.31
    11 Mar 2024 $1.31 $-0.02 -1.50% 1,500,244 $1.33 $1.36 $1.31
    08 Mar 2024 $1.34 $0.02 1.53% 2,154,241 $1.34 $1.35 $1.31
    07 Mar 2024 $1.31 $0.04 3.15% 3,001,730 $1.29 $1.33 $1.26
    06 Mar 2024 $1.27 $-0.02 -1.55% 4,040,773 $1.27 $1.29 $1.21
    05 Mar 2024 $1.29 $0.17 15.11% 6,800,417 $1.22 $1.32 $1.22
    04 Mar 2024 $1.13 $-0.04 -3.42% 2,424,998 $1.19 $1.19 $1.12
    01 Mar 2024 $1.17 $0.06 5.41% 5,249,034 $1.13 $1.18 $1.09
    29 Feb 2024 $1.11 $-0.07 -5.93% 10,909,382 $1.17 $1.18 $1.11
    28 Feb 2024 $1.18 $-0.09 -7.11% 12,931,275 $1.17 $1.25 $1.12
    27 Feb 2024 $1.27 $-0.12 -8.66% 4,760,651 $1.36 $1.37 $1.26

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    15 Mar 2024 Sally Evans Exercise 16,450 $25,000
    Conversion of securities. vwap, 16,450 NED Share Rights
    15 Mar 2024 Sally Evans Buy 16,450 $25,000
    Conversion of securities. vwap
    15 Mar 2024 Charlie Taylor Buy 16,450 $25,000
    Conversion of securities.
    15 Mar 2024 Charlie Taylor Exercise 16,450 $25,000
    Conversion of securities. vwap, 16,450 NED Share Rights
    28 Feb 2024 Maxine Jaquet Issued 512,645 $1,499,999
    Issue of securities. vwap, 884,504 Performance Rights
    30 Jan 2024 Maxine Jaquet Expiry 1,667,805 $2,334,927
    Options expired.
    21 Dec 2023 Charlie Taylor Buy 50,000 $74,500
    On-market trade.
    19 Dec 2023 Charlie Taylor Buy 50,000 $74,815
    On-market trade.
    14 Dec 2023 Maxine Jaquet Issued 112,078 $134,493
    Rights issue.
    14 Dec 2023 Sally Evans Issued 9,557 $11,468
    Rights issue.
    14 Dec 2023 Sally Evans Issued 4,110 $4,932
    Rights issue.
    14 Dec 2023 John Mattick Issued 7,546 $9,055
    Rights issue.
    14 Dec 2023 John Mattick Issued 4,136 $4,963
    Rights issue.
    14 Dec 2023 Gordon Davis Issued 15,277 $18,332
    Rights issue.
    14 Dec 2023 Gordon Davis Issued 11,018 $13,221
    Rights issue.
    14 Dec 2023 Kathryn (Kate) McKenzie Issued 551 $661
    Rights issue.
    14 Dec 2023 Kathryn (Kate) McKenzie Issued 9,590 $11,508
    Rights issue.
    13 Dec 2023 Sally Evans Issued 32,900 $50,000
    Issue of securities. 32,900 NED Share Rights, vwap
    13 Dec 2023 Charlie Taylor Issued 32,900 $50,000
    Issue of securities. VWAP, 32,900 NED Share Rights
    04 Dec 2023 Kathryn (Kate) McKenzie Buy 53,000 $80,560
    On-market trade.
    01 Dec 2023 Michael Stanford Buy 32,468 $49,838
    On-market trade.
    11 Sep 2023 Jennifer (Jenny) Macdonald Buy 8,000 $20,229
    On-market trade.
    04 Sep 2023 Sally Evans Exercise 6,038 $20,000
    Conversion of securities. cash equivalent using the volume weighted average price
    04 Sep 2023 Sally Evans Buy 6,038 $20,000
    Conversion of securities. cash equivalent using the volume weighted average price
    04 Sep 2023 John Mattick Exercise 7,547 $25,000
    Conversion of securities. cash equivalent using the volume weighted average
    price
    04 Sep 2023 John Mattick Buy 7,547 $25,000
    Conversion of securities. cash equivalent using the volume weighted average
    price
    04 Sep 2023 Gordon Davis Buy 12,075 $40,000
    Conversion of securities. cash equivalent using the volume weighted
    average price
    04 Sep 2023 Gordon Davis Exercise 12,075 $40,000
    Conversion of securities. cash equivalent using the volume weighted
    average price
    01 Sep 2023 Kathryn (Kate) McKenzie Buy 20,000 $55,200
    On-market trade.
    31 Aug 2023 Jennifer (Jenny) Macdonald Buy 22,500 $61,200
    On-market trade.
    31 Aug 2023 Maxine Jaquet Issued 41,066 $114,984
    Conversion of securities.
    31 Aug 2023 Maxine Jaquet Exercise 41,066 $114,984
    Conversion of securities. 371,859 Performance Rights
    30 May 2023 Maxine Jaquet Issued 371,859 $1,160,200
    Issue of securities. 4,12,925 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Michael Philip Stanford Non-Executive Director Sep 2023
    Dr Stanford AM is a Non-Executive Director across a range of industries including healthcare, aged care and education. His experience includes ASX-listed businesses, private equity backed companies and not for profit organisations, and includes dealing with Federal and State Governments Commencing his career as a Doctor, Michael progressed into hospital administration and brings over 20 years experience as a Chief Executive Officer and Managing Director of large multi-campus and multi service health care organisations with national and international areas of operation, including St John of God Health Care, Australian Hospital Care Ltd, North-Western Health. North-Eastern Health Care Network and Austin & Repatriation Medical Centre. Dr Stanford is a former Non-Executive Director of Healthscope, Virtus Health and Australian Clinical Labs. He is currently the Chair of Diabetes Australia and genU, a disability support service provider. He is also a board member for the Royal Australian College of General Practitioners.
    Professor John Mattick Non-Executive Director Mar 2022
    Professor Mattick is a Professor in the School of Biotechnology and Biomolecular Science at UNSW Sydney. From 2018 to 2010, he was Chief Executive of Genomics England, which was established by the UK government to foster the use of genetic information in healthcare. He was Director of the Garvan Institute of Medical Research in Sydney from 2012 to 2018, where he established throughput NATA accredited DNA sequencing and genome analysis facilities. John was a member of the Australian Health Ethics Committee of the National Health & Medical Research Council from 1997 to 2003, an advisor to the Australian Law Reform Commission's Inquiry into the Protection of Human Genetic Information and Gene Patenting & Human Health, and the AHEC Committee to Revise the Ethical Guidelines on Assisted Reproductive Technology. He is a member of the Risk Management Committee.
    Mr Gordon Richard Davis Non-Executive Director Aug 2015
    Mr Davis has been an executive or non-executive director of ASX listed companies for 17 years. Before becoming a Non-Executive Director, he was Managing Director of AWB Limited between 2006 and 2010 and had a career, managing operating businesses in chemicals and agriculture. Gordon joined the Healius Board at a time of some corporate uncertainty, and has experience in governance and business transformation. He served as Policy Advisor to the federal Leader of the Opposition from 1990 to 1993 in the fields of environment, science and resources.
    Mr Paul Anderson Chief Executive OfficerManaging Director Mar 2024
    Mr Anderson had previously been Chief Executive Officer -Network Ten and Executive Vice President,ViacomCBS Networks Australia & NZ from 2015 to 2020, and was CFO and COO of Network Ten prior to that.
    Ms Kathryn (Kate) Mary McKenzie Non-Executive Director Feb 2021
    Ms McKenzie has experience in change management and digital transformation. She started her career in the public sector, where among other things, she was involved in aspects of health policy, including a state-based review of health system and re-negotiation of a Medicare agreement, and had involvement in working with Treasury on health budget allocations and methodologies. Kate joined Telstra in 2004 and held a range of executive roles in strategy, marketing, products and operations (responsible for networks, IT, field services and property). She was CEO of Chorus, a publicly listed NZ telco, for three years from 2017.She was appointed Chair of the Risk Management Committee in January 2023 and is a member of the People & Governance Committee.
    Ms Sally Evans Non-Executive Director Aug 2018
    Ms Evans has over 30 years of experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the broader Asia Pacific region. With leadership experience, Sally moved to asset management in social infrastructure covering debt and equity raisings, investor relations, acquisitions and governance. She is Chair of the People & Governance Committee and a member of the Risk Management Committee.
    Mr Charlie Taylor Non-Executive Director Mar 2023
    Mr Taylor has over 30 years of experience in advisory having recently retired as Senior Partner at McKinsey where he led the Health and Public Sector practices. He has advised many of Australia's private and public sector healthcare organisations on topics including strategy, digital, operations and growth transformations, global expansion and supply chains, mergers and acquisitions and board governance. Charlie initiated multi-year research efforts on healthcare, COVID response, productivity and innovation and has published articles and reports on healthcare reform lessons from around the globe. Charlie is currently a part-time senior board advisor at McKinsey for the Health and Public Sector practice, a Director of MacLauglin River Pastoral Company, a member of the strategic advisory committee For Purpose Investment Partners and was recently appointed as Chair of the NSW Innovation and Productivity Commission. Charlie is the Honorary Federal Treasurer for the Liberal Party and a Board member on the Federal Executive. is a member of the People & Governance Committees.
    Mr Ravi Jeyaraj Non-Executive Director Nov 2023
    --
    Mrs Mary Weaver Company Secretary Mar 2023
    -
    Mr Stephen Humphries Company Secretary Mar 2023
    -
    Paul Anderson Chief Financial Officer
    -
    Mary Weaver Company Secretary
    -
    Stephen Humphries Company Secretary
    -
    Jan van Rooyen Group Executive
    -
    Janet Payne Group Executive Corporate Affairs
    -
    Mark Neeham Group Executive Government Affairs
    -
    John McKechnie Group Executive Pathology
    -
    Jon Eide Group Executive Commercial and Customer
    -
    Phil Lucas Group Executive Lumus Imaging
    -
    Arjun Narang Group Executive Operations Transformation
    -
    Prasad Arav Group Executive. Digital and Technology
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED(i) 179,525,030 31.51%
    Citicorp Nominees Pty Limited 113,011,084 19.84%
    J P Morgan Nominees Australia Pty Limited 101,426,357 17.80%
    National Nominees Limited 41,431,994 7.27%
    Argo Investments Limited 19,132,634 3.36%
    Bnp Paribas Noms Pty Ltd <Drp> 13,878,419 2.44%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/ 3,770,723 0.66%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 3,577,160 0.63%
    Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> 3,367,888 0.59%
    Ubs Nominees Pty Ltd 3,150,206 0.55%
    Rinrim Pty Ltd 2,362,047 0.41%
    BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 1,204,931 0.21%
    Ecapital Nominees Pty Limited <Accumulation A/C> 1,032,081 0.18%
    Alphagen Capital Pty Ltd 1,000,000 0.18%
    HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED(ii) 704,441 0.12%
    Joromada Pty Ltd 680,000 0.12%
    Netwealth Investments Limited <Wrap Services A/C> 636,689 0.11%
    Mr Gregory Anthony Thomas Bateman 636,213 0.11%
    Nulis Nominees (Australia) Limited <Navigator Mast Plan Sett A/C> 580,893 0.10%
    HSBC Custody Nominees (Australia) Limited Gsco Eca 569,088 0.10%

    Profile

    since

    Note